Patent classifications
C07D265/34
Anti-fibrotic compounds
Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein. (Formula (I))
[6,6] FUSED BICYCLIC HDAC8 INHIBITORS
The present invention is directed to compounds of Formula I:
##STR00001## and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R.sub.1, R.sub.2, R.sub.2, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
[6,6] FUSED BICYCLIC HDAC8 INHIBITORS
The present invention is directed to compounds of Formula I:
##STR00001## and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers or thereof, wherein R.sub.1, R.sub.2, R.sub.2, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.
Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes
The present application relates to mass spectrometry methods for use in identifying proteins or other biomolecules which are bound irreversibly by test compounds.
Reagents and Methods for Analysis of Proteins and Metabolites Targeted by Covalent Probes
The present application relates to mass spectrometry methods for use in identifying proteins or other biomolecules which are bound irreversibly by test compounds.
[6,6] fused bicyclic HDAC8 inhibitors
The present invention is directed to compounds of Formula I: ##STR00001## and pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2, R.sub.2, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein, useful as inhibitors of zinc-dependent histone deacetylases (HDACs) and in the treatment of diseases or disorders associated with HDACs.
[6,6] fused bicyclic HDAC8 inhibitors
The present invention is directed to compounds of Formula I: ##STR00001## and pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2, R.sub.2, L, X, W, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein, useful as inhibitors of zinc-dependent histone deacetylases (HDACs) and in the treatment of diseases or disorders associated with HDACs.
Spiro-cyclic amine derivatives as S1P modulators
The present invention relates spiro-cyclic amine derivatives of the formula (I) wherein R1; R2; R3; Q; W-T-; R5; Z; and A have the definitions provided in the claims; or a pharmaceutically acceptable salt, a solvate or hydrate thereof or one or more N-oxides thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of diseases and conditions in which (a) S1P receptor (s) is (are) involved. ##STR00001##
Spiro-cyclic amine derivatives as S1P modulators
The present invention relates spiro-cyclic amine derivatives of the formula (I) wherein R1; R2; R3; Q; W-T-; R5; Z; and A have the definitions provided in the claims; or a pharmaceutically acceptable salt, a solvate or hydrate thereof or one or more N-oxides thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of diseases and conditions in which (a) S1P receptor (s) is (are) involved. ##STR00001##
VISIBLE LIGHT-ACTIVATED DYES AND METHODS OF USE THEREOF
Disclosed herein are photoactivable fluorophores comprising one or more thiocarbonyl groups as well as conjugates and compositions thereof. The present disclosure also provides methods of preparing photoactivatable fluorophores as well as methods of imaging using the photoactivatable fluorophores, conjugates, and compositions of the present disclosure.